Literature DB >> 9504056

Histoplasmosis in the acquired immunodeficiency syndrome.

J Wheat1.   

Abstract

Opportunistic infections are common and major causes of morbidity in patients with AIDS. Endemic mycoses pose serious risks for patients in certain parts of the world. Histoplasmosis occurs in 2-5% of patients with AIDS in the Ohio and Mississippi River valleys of the United States and in over 25% of patients from a few cities. Antigen testing has become a highly useful method for diagnosing histoplasmosis rapidly, evaluating the response to treatment and diagnosing relapse. Treatment with amphotericin B or itraconazole is effective (90% or higher) if the patient is not seriously ill at the time of diagnosis but the mortality approaches 50% for those with multiorgan failure. Itraconazole blood levels should be monitored and drugs that impair the absorption or accelerate the metabolism of itraconazole should be avoided. Prophylaxis with itraconazole may be appropriate in areas with an incidence of histoplasmosis. A recently completed study in cities which have unusually high rates of histoplasmosis will provide greater insight into the role of prophylactic antifungal therapy.

Entities:  

Mesh:

Year:  1996        PMID: 9504056

Source DB:  PubMed          Journal:  Curr Top Med Mycol        ISSN: 0177-4204


  29 in total

1.  Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS.

Authors:  L Joseph Wheat; Patricia Connolly; Nicholas Haddad; Ann Le Monte; Edward Brizendine; Richard Hafner
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

2.  Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits.

Authors:  A H Groll; D Mickiene; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  Development of a novel antigen detection test for histoplasmosis.

Authors:  B L Gomez; J I Figueroa; A J Hamilton; B L Ortiz; M A Robledo; A Restrepo; R J Hay
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

4.  Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice.

Authors:  P Connolly; L J Wheat; C Schnizlein-Bick; M Durkin; S Kohler; M Smedema; J Goldberg; E Brizendine; D Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

5.  DIAGNOSIS OF HISTOPLASMOSIS.

Authors:  Allan Jefferson Guimarães; Joshua D Nosanchuk; Rosely Maria Zancopé-Oliveira
Journal:  Braz J Microbiol       Date:  2006-01       Impact factor: 2.476

6.  Cutaneous and bone marrow histoplasmosis after 18 years of renal allograft transplant.

Authors:  K Y Ibrahim; N B Carvalho; E V Mimicos; H Yeh-Li; M N Sotto; F O S França
Journal:  Mycopathologia       Date:  2014-08-06       Impact factor: 2.574

7.  Detection of the 70-kilodalton histoplasma capsulatum antigen in serum of histoplasmosis patients: correlation between antigenemia and therapy during follow-up.

Authors:  B L Gómez; J I Figueroa; A J Hamilton; S Diez; M Rojas; A Tobón; A Restrepo; R J Hay
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

8.  Diagnostic value of culture and serological tests in the diagnosis of histoplasmosis in HIV and non-HIV Colombian patients.

Authors:  Karen Arango-Bustamante; Angela Restrepo; Luz Elena Cano; Catalina de Bedout; Angela Maria Tobón; Angel González
Journal:  Am J Trop Med Hyg       Date:  2013-09-16       Impact factor: 2.345

9.  PCR assay for identification of histoplasma capsulatum based on the nucleotide sequence of the M antigen.

Authors:  Herbert Leonel de Matos Guedes; Allan Jefferson Guimarães; Mauro de Medeiros Muniz; Claudia Vera Pizzini; Andrew John Hamilton; José Mauro Peralta; George S Deepe; Rosely M Zancopé-Oliveira
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

Review 10.  Histoplasma capsulatum at the host-pathogen interface.

Authors:  Joshua D Nosanchuk; Attila Gacser
Journal:  Microbes Infect       Date:  2008-07-10       Impact factor: 2.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.